Rituximab Market Size

Rituximab Market size was over USD 4.03 billion in 2024 and is anticipated to cross USD 27.13 billion by 2037, witnessing more than 15.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of rituximab is estimated at USD 5.11 billion.

The increasing incidences of non-Hodgkin’s lymphoma (NHL) are expected to boost the market growth of rituximab. As per the American Cancer Society, NHL is one of the most common diseases in the USA. Around 77,200 cases were registered in 2020 in the US, the incidences are anticipated to grow rapidly due to the rising cases of cancer in the region.

In case of an autoimmune disease, the immune system attacks the healthy cells of the body. Thus, the rising prevalence of autoimmune diseases is likely to accelerate the growth of the rituximab market. According to the reports by University of Oxford, about 22 million are affected by autoimmune diseases yearly. These factors are bolstering the market growth of rituximab.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of rituximab is estimated at USD 5.11 billion.

The rituximab market size was over USD 4.03 billion in 2024 and is anticipated to cross USD 27.13 billion by 2037, witnessing more than 15.8% CAGR during the forecast period i.e., between 2025-2037. Increasing demand for monoclonal antibodies, increasing collaborations for the development of new products and investment in healthcare sector will drive the market growth.

North America industry is anticipated to dominate majority revenue share of 45% by 2037, fuelled by increased government spending on cancer research as well as the presence of major pharmaceutical companies in the region.

The major players in the market are Amgen Inc, Henlius Biotech, Inc., Nordic Nanovector ASA, Biocon Biologics Ltd, Pfizer Inc., Chugai Pharmaceuticals, Zenyaku Kogyo Co. Ltd, SymBio Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin Co. Ltd

Rituximab Market Size